Work Here?
Abata Therapeutics
Work Here?
Develops Treg-based therapies for autoimmune diseases
Abata Therapeutics
Work Here?
Develops Treg-based therapies for autoimmune diseases
Overview
Abata Therapeutics develops therapies for autoimmune diseases, with a focus on type 1 diabetes, using regulatory T cell (Treg) therapy. Its lead product ABA 201 is a Treg cell therapy for patients with residual beta cell function and is in IND-enabling studies with clinical trials expected in 2025. The therapy aims to dampen autoimmune attacks and preserve insulin-producing beta cells, with ElevateBio supporting process development and scalable manufacturing. The goal is to bring autoimmune treatments to patients through R&D, partnerships, and eventual commercialization, leveraging a focused niche and collaboration to advance toward approved therapies.
About Abata Therapeutics
Industries
Biotechnology
Healthcare
Company Size
1-10
Company Stage
Early VC
Total Funding
$190M
Headquarters
Cambridge, Massachusetts
Founded
2021
Simplify's Take
What believers are saying
- Bristol Myers Squibb investment in August 2024 funds clinical advancement.
- ElevateBio partnership scales Treg manufacturing for trials.
- Expert hires like Joanne Beck as CTO in September 2024 boost execution.
What critics are saying
- Kyverna's KYV-101 captures progressive MS first-mover advantage.
- Quell's QEL-001 allogeneic Tregs superior in type 1 diabetes trials.
- FDA holds ABA-101 IND due to ElevateBio Treg instability.
What makes Abata Therapeutics unique
- Abata engineers TCR-targeted Tregs for tissue-specific autoimmune treatment.
- ABA-101 targets progressive MS CNS inflammation lacking therapies.
- ABA-201 preserves beta cells in type 1 diabetes patients.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$190M
Above
Industry Average
Funded Over
2 Rounds
Lightspeed Venture PartnersCompany News
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) - Abata Therapeutics, a clinical-stage biotech company focused on transforming lives with Treg therapies for severe autoimmune and inflammatory diseases, today announced the appointment of Joanne Beck, Ph.D., as chief technical officer.
WATERTOWN, Mass., Aug. 15, 2024 (GLOBE NEWSWIRE) — Abata Therapeutics, a company focused on transforming lives with Treg therapies for... Read More
Founded by pioneers in Treg biology, TCR and antigen discovery, disease pathogenesis, and molecular and imaging biomarkers, Abata has developed a differentiated product engine to create engineered Treg cell therapies that are tissue-specific, robust, and durable.
Abata Therapeutics, a company focused on translating the biology of regulatory T cells (Tregs) into transformational medicines for patients with severe autoimmune and inflammatory diseases, today announced the appointment of Leonard "Lenny" Dragone, M.D., Ph.D., as its new chief medical officer.
Abata has collaborated with ElevateBio BaseCamp to develop a manufacturing process that engineers and grows Tregs for therapeutic use.
There are no jobs for Abata Therapeutics right now.
Find jobs on Simplify and start your career today
About Abata Therapeutics
Industries
Biotechnology
Healthcare
Company Size
1-10
Company Stage
Early VC
Total Funding
$190M
Headquarters
Cambridge, Massachusetts
Founded
2021
There are no jobs for Abata Therapeutics right now.
Find jobs on Simplify and start your career today